UC exacerbation has been described not only in patients receiving sunitinib and sorafenib, two oral multiple kinase inhibitors targeting not only the VEGF pathway, but also other receptors as well, such as platelet-derived growth factor receptor alpha (PDGFRA), which are potentially involved in the pathophysiology of IBD [12,13]. This evidence concerns the gene PDGFRA and inflammatory bowel disease.